Exagen will pay Cypress up to $8 million in upfront and milestone payments as well as additional royalty payments for the business.
Under the deal, Marina will receive $750,000 up front, and stands to be paid as much as $27 million in milestones.
The firm offers its Avise PG test as a service for physicians making decisions about methotrexate therapy.
Cypress will pay up to $5 million for the technology, which it plans to use for diagnosis and therapeutic monitoring of lupus patients.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.